CVALF Covalon Technologies Ltd.

Covalon Technologies Ltd. researches, develops, manufactures, commercializes, and licenses medical technologies and products in the United States, Canada, Europe, the Middle East, Asia, Latin America, and internationally. The company has three platform technologies, including collagen matrix platform that is used to manufacture a family of products that treat chronic and infected wounds, such as diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; antimicrobial silicone adhesive platform, which is used in a family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone; and medical coating platform, a proprietary process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. It sells wound care dressing, surgical and peri-operative, and infection management products under the Covalon brand name. The company also offers development contracts, licensing agreements, and distribution contracts services. It provides its technologies, products, and services to various health care providers, such as hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians' offices. The company is headquartered in Mississauga, Canada.

Note: This is not a U.S. company, but they cross-list their shares on the U.S. over-the-counter market - see the related symbol CV:COV.

$1.84    OTCQX
As of 11/29/2021     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  
IPO date:  04/17/2007
Outstanding shares:  25,868,677
Average volume:  2,561
Market cap:   $48,012,265
Current dividend yield:  0.00%
CUSIP:    
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   -44.63
PB ratio:   5.26
PS ratio:   2.24
Return on equity:   -11.81%
Net income %:   -3.92%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy